AdvaMed members manufacture and ship instruments and high-quality tests that, together with key inputs from our colleagues across the testing ecosystem (e.g., PPE, plastics, swabs, etc.), serve as the backbone of supply for the U.S. testing response to COVID.

AdvaMed has created a national COVID-19 Diagnostic Supply Registry to support state and federal governments in their pandemic responses. AdvaMed and its members are fully committed to providing key data to policymakers and the public in our collective work mobilizing against the pandemic.

AdvaMed is leading this data tracking and analysis effort, driven by thirteen leading diagnostic manufacturers whose tests together comprise ~75-80% of the COVID-19 Molecular IVD tests on the market in the U.S.

Key Data-Driven Summary of the U.S. COVID Testing Supply

Last updated December 17th, 2021

- Across leading COVID diagnostic manufacturers, ~667 million molecular COVID-19 tests have been shipped since March 2020, including ~504 million commercial tests and ~163 million extraction reagents.
- Registry participants collectively shipped ~8.2 million molecular tests for the week ending December 11th.
- Daily Molecular tests run decreased by 12% during the week ending December 11th, compared to the previous week, with an average of ~1.5 million1 tests per day.
- Additionally: laboratory-based Serology/Antibody and Antigen testing are widely available throughout the U.S., with increasing availability of point-of-care testing – including over-the-counter home testing.

667 Million Molecular Tests Shipped Since March 20202

---

1. Averaged over the week to account for fluctuations by day of the week. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests). 2. IVD and LDT molecular diagnostic test shipments to hospital, reference, and other laboratories.